Zevra Therapeutics, Inc. (ZVRA): Capital Expenditures
$835.0K
Year ended 2025-12-31
$775.0K
Trailing 12 months to 2026-06-30
+107.8%
3-year compound annual growth
+90.8%
5-year compound annual growth
+20.0%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $835.0K | n/a | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $0 | -100.0% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $296.0K | +218.3% | 2025-03-12, From 2023-01-01 |
| 2022-12-31 | $93.0K | -8.8% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $102.0K | +209.1% | 2023-03-07, From 2021-01-01 |
| 2020-12-31 | $33.0K | +26.9% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $26.0K | +23.8% | 2021-03-12, From 2019-01-01 |
| 2018-12-31 | $21.0K | -88.4% | 2020-02-28, From 2018-01-01 |
| 2017-12-31 | $181.0K | -71.9% | 2019-03-01, From 2017-01-01 |
| 2016-12-31 | $643.0K | +376.3% | 2018-03-30, From 2016-01-01 |
| 2015-12-31 | $135.0K | +187.2% | 2018-03-30, From 2015-01-01 |
| 2014-12-31 | $47.0K | n/c | 2017-03-10, From 2014-01-01 |
| 2013-12-31 | $51.0K | n/a | 2016-03-16, From 2013-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $835.0K | n/a |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $1.52M | -23.6% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $289.0K | -2.0% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $1.19M | -48.6% |
| Xencor Inc (XNCR) | 2025-12-31 | $3.15M | -48.3% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $24.81M | +535.1% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $13.41M | -27.1% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $8.30M | -0.6% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $339.0K | -39.8% |
Compare ZVRA, ZYME, URGN, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗